Drug Trial News

RSS

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

A new drug may improve memory problems in people with moderate Alzheimer's disease, according to a phase IIa study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741.

12 Mar 2013

Addition of niacin to statin does not improve HDL function

While two large clinical trials recently showed that adding niacin to statin therapy failed to improve clinical outcomes despite a significant increase in HDL-C levels, little is known about exactly why the increased HDL-C levels did not reduce the risk of cardiovascular events, including heart attack and stroke.

12 Mar 2013

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.

12 Mar 2013

$Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction$

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA.

12 Mar 2013

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis.

12 Mar 2013

Combination of INF and glatiramer acetate does not reduce MS progression

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.

12 Mar 2013

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.

12 Mar 2013

$Sildenafil does not help heart failure patients with preserved ejection fraction$

Sildenafil does not help heart failure patients with preserved ejection fraction

A commonly used erectile dysfunction drug, sildenafil, doesn't help patients who have heart failure with preserved ejection fraction, a condition in which the heart's lower chambers are stiff and cannot relax and fill fully between beats.

12 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat prevalent inflammatory diseases, such as osteoarthritis (Ampion) and diabetic macular edema (Optina) and sexual dysfunction (Zertane) announced FDA acceptance of its POPE questionnaire, a modification of the Premature Ejaculation Profile (PEP) questionnaire that was used in the two successful Zertane Phase 3 clinical trials completed in Europe.

11 Mar 2013

IP chemotherapy increases survival in patients with advanced ovarian cancer

Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark Gynecologic Oncology Group (GOG) trials comprising 876 patients.

11 Mar 2013

NCI-sponsored study to evaluate rosuvastatin for prevention of colon cancer

With March designated as Colorectal Cancer Awareness Month, the North Shore-LIJ Cancer Institute is enrolling people who were recently treated for colon cancer in a polyp prevention study. This National Cancer Institute (NCI)-sponsored study evaluates the cholesterol drug, rosuvastatin (Crestor), as a treatment to reduce the risk of colon cancer.

11 Mar 2013

GLP1 medications appear to protect diabetic patients from heart failure

A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure, according to a study at Henry Ford Hospital in Detroit.

11 Mar 2013

Aarbepoetin alfa does not improve anemic heart failure patients' health

Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients -darbepoetin alfa - does not improve patients' health, nor does it reduce their risk of death from heart failure.

11 Mar 2013

Adrenocorticotropic hormone may help treat people with multiple sclerosis

A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.

11 Mar 2013

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.

11 Mar 2013

Inclacumab reduces damage to heart muscle during angioplasty

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.

11 Mar 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

A new multi-site study reveals patients with drug-resistant HIV can safely achieve viral suppression - the primary goal of HIV therapy - without incorporating the traditional class of HIV medications into their treatment regimen.

8 Mar 2013

Drug Trial News

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

Addition of niacin to statin does not improve HDL function

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

Sildenafil does not improve exercise capacity in HF patients with preserved ejection fraction

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Combination of INF and glatiramer acetate does not reduce MS progression

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Sildenafil does not help heart failure patients with preserved ejection fraction

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

IP chemotherapy increases survival in patients with advanced ovarian cancer

NCI-sponsored study to evaluate rosuvastatin for prevention of colon cancer

GLP1 medications appear to protect diabetic patients from heart failure

Aarbepoetin alfa does not improve anemic heart failure patients' health

Adrenocorticotropic hormone may help treat people with multiple sclerosis

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Inclacumab reduces damage to heart muscle during angioplasty

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Patients with drug-resistant HIV can safely achieve viral suppression without NRTIs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News